# US 10,869,868 B2 · Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,868 B2
- Document ID: US10869868B2
- Status: Granted
- Kind: B2
- Application number: 16/072,876
- Filed: 2017-01-26
- Published: 2019-10-10
- Granted: 2020-12-22
- Earliest claimed: 2016-01-26
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Scott A. Armstrong
- Web page: https://patentgrep.com/patent/US10869868B2

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.

## Claims

### Claim 1

A method for inhibiting proliferation and/or inducing apoptosis in a leukemia cell, comprising contacting the leukemia cell with an inhibitor of interaction between MLL and menin, wherein the leukemia cell exhibits an NPM1 mutation, and does not exhibit a genetic mutation, alteration, and/or abnormality that is an MLL-translocation (MLL-t), an MLL-rearrangement (MLL-r), or an MLL-partial tandem duplication (MLL-PTD).

### Claim 2 (depends on 1)

The method of claim 1, wherein the leukemia cell is selected from the group consisting of an acute lymphocytic leukemia (ALL) cell and an acute myeloid leukemia (AML) cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor has an IC50 of from about 100 nM to about 10 μM, or from about 250 nM to about 5 μM, or from about 500 nM to about 1 μM.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitor is selected from the group consisting of MI-0202, MI-503, MI-463, MI-136, ML-225, a compound of the formula:
wherein R1, R2, R3, R4, R5, R6, R7, and R8 are each independently selected from the group consisting of: H, substituted or non-substituted alkyl, substituted or non-substituted alkoxy, a halogen (e.g. F, CI, Br, I, and At), a ketone, a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with substituted or non-substituted alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring fused or attached to the thienopyrimidine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, or a hydrogen bond donor or a hydrogen bond acceptor; Z is S or O or NH or CH—CH; W is present or absent and is NH or NH—(CH2)n (n is an integer between 0 and 10), or (CH2)n (n is an integer between 0 and 10) or O or O—(CH2)n (n is an integer between 0 and 10); X and Y are each independently N or C; and m is an integer between 0 and 3 or pharmaceutically acceptable salts of thereof: or
a compound of the formula:
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of: H, substituted or non-substituted alkyl, substituted or non-substituted alkoxy, a halogen, a ketone, a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring fused to the benzodiazepine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic or heterocyclic aromatic ring comprising carbon; or pharmaceutically acceptable salts thereof.

### Claim 5

A method for treating leukemia in a patient in need thereof, comprising:
administering to the patient an effective amount of an inhibitor of interaction between MLL and menin;
wherein the patient exhibits an NPM1 mutation, and does not exhibit a genetic mutation, alteration, and/or abnormality selected from the group consisting of an MLL-t, an MLL-r, and an MLL-PTD.

### Claim 6 (depends on 5)

The method of claim 5, wherein the leukemia is selected from the group consisting of an acute lymphocytic leukemia (ALL) and an acute myeloid leukemia (AML).

### Claim 7 (depends on 5)

The method of claim 5, wherein the inhibitor has an IC50 of from about 100 nM to about 10 μM, or from about 250 nM to about 5 μM, or from about 500 nM to about 1 μM.

### Claim 8 (depends on 5)

The method of claim 5, wherein the inhibitor is selected from the group consisting of MI-0202, MI-503, MI-463, MI-136 and ML-225, and pharmaceutically acceptable salts or free base versions thereof or
a compound of the formula:
wherein R1, R2, R3, R4, R5, R6, R7, and R8 are each independently selected from the group consisting of: H, substituted or non-substituted alkyl, substituted or non-substituted alkoxy, a halogen (e.g. F, CI, Br, I, and At), a ketone, a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with substituted or non-substituted alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more of nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring fused or attached to the thienopyrimidine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic or heterocyclic aromatic ring comprising carbon atoms and one or more nitrogen, oxygen and/or sulfur members fused to another aromatic ring, or a hydrogen bond donor or a hydrogen bond acceptor; Z is S or O or NH or CH—CH; W is present or absent and is NH or NH—(CH2)n (n is an integer between 0 and 10), or (CH2)n (n is an integer between 0 and 10) or O or O—(CH2)n (n is an integer between 0 and 10); X and Y are each independently N or C; and m is an integer between 0 and 3; or pharmaceutically acceptable salts of thereof; or
a compound of the formula:
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of: H, substituted or non-substituted alkyl, substituted or non-substituted alkoxy, a halogen, a ketone, a carbocyclic ring, an aromatic ring, a heterocyclic aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, a heterocyclic non-aromatic ring comprising carbon and one or more nitrogen, oxygen and/or sulfur members which may be non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic aromatic or non-aromatic ring fused to the benzodiazepine ring system non-substituted or substituted with alkyl, aryl, halogen, hydrogen bond donor or acceptor, carbocyclic or heterocyclic aromatic ring comprising carbon; or pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 5)

A method according to claim 5 further comprising co-administering to the patient an effective amount of a DOT1L inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the DOT1L inhibitor inhibits DOT1L with an IC50 of from about 100 nM to about 10 μM, or from about 250 nM to about 5 μM, or from about 500 nM to about 1 μM.

### Claim 11 (depends on 9)

The method of claim 9 wherein the DOT1L inhibitor is selected from the group consisting of a purine, a carbocycle-substituted purine, a 7-deazapurine, EPZ00477, EPZ005676, SGC-0946, SYC-522, SYC-534, and SYC-687.

### Claim 12 (depends on 1)

The method of claim 1, wherein MLL is MLL1.

### Claim 13 (depends on 5)

The method of claim 5, wherein MLL is MLL1.